At the time of writing, Pacira BioSciences Inc [PCRX] stock is trading at $22.94, up 3.94%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PCRX shares have gain 4.04% over the last week, with a monthly amount drifted -1.21%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on July 25, 2025, when Truist upgraded its rating to a Buy but kept the price target unchanged to $30 for it. Previously, Truist upgraded its rating to Hold on January 30, 2025, and elevated its price target to $25. On August 13, 2024, downgrade downgraded it’s rating to Sell and revised its price target to $8 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $14 on August 12, 2024. Raymond James downgraded its rating to a Mkt Perform. Piper Sandler downgraded its rating to Neutral for this stock on August 12, 2024, and downed its price target to $11. In a note dated August 12, 2024, JP Morgan downgraded an Underweight rating on this stock and revised its target price from $45 to $10.
For the past year, the stock price of Pacira BioSciences Inc fluctuated between $11.16 and $27.64. Currently, Wall Street analysts expect the stock to reach $36 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $22.94 at the most recent close of the market. An investor can expect a potential return of 56.93% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
According to Pacira BioSciences Inc [NASDAQ:PCRX], the company’s sales were 702.77M for trailing twelve months, which represents an 1.08% jump. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.1%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.13 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Pacira BioSciences Inc [NASDAQ:PCRX] has a current ratio of 2.41. In addition, the Quick Ratio stands at 1.99 and the Cash Ratio stands at 0.9. Considering the valuation of this stock, the price to sales ratio is 1.51, the price to book ratio is 1.33.
Transactions by insiders
Recent insider trading involved RIKER LAUREN, Senior Vice President, Finance, that happened on Jun 04 ’25 when 5578.0 shares were sold. Chief Administrative Officer, WILLIAMS KRISTEN completed a deal on Jun 04 ’25 to sell 14376.0 shares. Meanwhile, Officer RIKER LAUREN bought 5579.0 shares on Jun 04 ’25.
